Aclaris Therapeutics (ACRS)

• Market cap: $726M
• 1 day: -2.26%
• 5 days: -1.7%
• 1 month: -1.7%
• 3 months: 19.82%
• 6 months: 44.04%
• Year to date: 80.56%
• 1 year: 239.87%
• 5 years: -65.52%
• 10 years: -73.68%
• Sector: Healthcare
• Industry: Biotechnology

About: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Employees: 73